The global malignant pleural effusion market is expected to garner a market value of US$ 4.5 Billion in 2023 and is expected to accumulate a market value of US$ 8.06 Billion by registering a CAGR of 6% in the forecast period 2023 to 2033. The increasing incidence of pleural effusion disease and rising awareness of advancement in pleural effusion treatment with different types of techniques in the current market works as a driver for the market. The market for Malignant Pleural Effusion registered a CAGR of 4% in the historical period 2018 to 2022.
Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period. Recent epidemiological data from WHO suggests that approximately more than one million pleural effusions are diagnosed in the United States each year.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4.5 Billion |
| Anticipated Forecast Value (2033) | US$ 8.06 Billion |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights. the market for Malignant Pleural Effusion reflected a value of 4% during the historical period, 2018 to 2022. Various factors such as awareness in wellness and health, the diagnostics, and pathology segment are improving in developing countries nowadays which grows the therapeutics market. The research and development activities in the field like emerging novel therapeutics, increasing the efficacy of medicine as well as treatment.
Selling campaigns initiated by global players are growing the market progressively. Increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of pleural effusions is fuelling market growth. Thus, the market for Malignant Pleural Effusion is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Increasing Incidence of Malignant Pleural Effusion disease post covid-19 pandemic to push the market growth
The increasing prevalence of Malignant Pleural Effusion disease is one of the biggest drivers of the market. After The covid-19 pandemic hit the world, various research was conducted to find a correlation between Covid-19 infection and pleural effusion.
For instance, the article “Prevalence and Clinical Outcomes of Pleural Effusion in Covid-19 Patients: A Systematic Review and Meta-Analysis” published in January 2022 showed that pleural effusion is related to the risk and prognosis of Covid-19 disease.
Pleural effusion can be used as a prognostic indicator to assess the likelihood of poorer outcomes in Covid-19 patients; as a result, the researchers of the above-mentioned research article advised that hospitalized Covid-19 patients with pleural effusion be handled promptly. Considering these in-depth studies, the pandemic showed a considerable impact on the market studied.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Malignant Pleural Effusion, less awareness of Malignant Pleural Effusion disease, and insubstantial treatment options are hampering the market growth.
Improvement in healthcare spending propelling the growth of Malignant Pleural Effusion in Asia Pacific
The Asia Pacific is expected to exhibit the fastest growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of malignant pleural effusion in the region.
Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the Pleural effusions treatment market worldwide.
High Prevalence of various diseases shaping the landscape for Malignant Pleural Effusion in North America
North America is anticipated to acquire a market share of about 45% in the forecast period. This growth is attributable to the rising prevalence of pleural effusions in the region. An article published by WebMD LLC in October 2021 stated that approximately 1.5 million pleural effusions are diagnosed in the United States every year and in industrialized countries, the estimated prevalence of pleural effusion is 320 cases per 100,000 people.
This ever-widening burden of the condition on the healthcare facilities is creating demand for the treatment globally, expected to fuel the market growth during the analysis period. Furthermore, the rising geriatric population is leading to an increase in the prevalence of various diseases, growing the health and economic burden.
As per the American Heart Association data updated in April 2022, nearly 115 million people in have hypertension, 100 million have obesity, 92 million have prediabetes, 26 million have diabetes, and 125 million have atherosclerotic cardiovascular diseases (CVD) United States, which are known to be the risk factors for the development of heart failure. Thus, the high burden of various diseases creates the risk of pleural effusions among the target population in the United States.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key start-up players in the Malignant Pleural Effusion market are-
Key players in the Malignant Pleural Effusion market are Allakos, iCo Therapeutics, Akari Therapeutics, and Santen.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 4.5 Billion |
| Market Value in 2033 | US$ 8.06 Billion |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
From 2017 to 2022, the Malignant Pleural Effusion market grew at a CAGR of 4%.
The global Malignant Pleural Effusion market is expected to grow with a 6% CAGR from 2023 to 2033.
As of 2033, the Malignant Pleural Effusion market is expected to reach US$ 8.06 Billion
According to the FMI analysis, hospitals account for the largest market share.
North America is expected to possess a 45% market share for the Malignant Pleural Effusion market.
The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
1. Executive Summary | Malignant Pleural Effusion Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033
5.3.1. Imaging Tests
5.3.2. Pleural Thoracocentesis
5.3.3. Pleural Fluid Cytology
5.3.4. Immunohistochemical Tests
5.3.5. Pleural Biopsy
5.3.6. Thoracoscopy/Pleuroscopy
5.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
6.3.1. Systemic Therapy
6.3.2. Therapeutic Thoracentesis
6.3.3. Thoracic Drainage and Pleurodesis
6.3.4. Indwelling Pleural Catheter
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals
7.3.2. Ambulatory Clinics
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. Asia-Pacific
8.3.6. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The US
9.2.1.2. Canada
9.2.2. By Diagnosis
9.2.3. By Treatment
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Diagnosis
9.3.3. By Treatment
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Diagnosis
10.2.3. By Treatment
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Diagnosis
10.3.3. By Treatment
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Benelux
11.2.1.2. France
11.2.1.3. Germany
11.2.1.4. Italy
11.2.1.5. Nordic
11.2.1.6. Spain
11.2.1.7. The UK
11.2.1.8. Rest of Western Europe
11.2.2. By Diagnosis
11.2.3. By Treatment
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Diagnosis
11.3.3. By Treatment
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Rest of Eastern Europe
12.2.2. By Diagnosis
12.2.3. By Treatment
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Diagnosis
12.3.3. By Treatment
12.3.4. By End User
12.4. Key Takeaways
13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Australia
13.2.1.6. New Zealand
13.2.1.7. Rest of APAC
13.2.2. By Diagnosis
13.2.3. By Treatment
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Diagnosis
13.3.3. By Treatment
13.3.4. By End User
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Diagnosis
14.2.3. By Treatment
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Diagnosis
14.3.3. By Treatment
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Diagnosis
15.1.2.2. By Treatment
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Diagnosis
15.2.2.2. By Treatment
15.2.2.3. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Diagnosis
15.3.2.2. By Treatment
15.3.2.3. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Diagnosis
15.4.2.2. By Treatment
15.4.2.3. By End User
15.5. Benelux
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Diagnosis
15.5.2.2. By Treatment
15.5.2.3. By End User
15.6. France
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Diagnosis
15.6.2.2. By Treatment
15.6.2.3. By End User
15.7. Germany
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Diagnosis
15.7.2.2. By Treatment
15.7.2.3. By End User
15.8. Italy
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Diagnosis
15.8.2.2. By Treatment
15.8.2.3. By End User
15.9. Nordic
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Diagnosis
15.9.2.2. By Treatment
15.9.2.3. By End User
15.10. Spain
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Diagnosis
15.10.2.2. By Treatment
15.10.2.3. By End User
15.11. The UK
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Diagnosis
15.11.2.2. By Treatment
15.11.2.3. By End User
15.12. Poland
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Diagnosis
15.12.2.2. By Treatment
15.12.2.3. By End User
15.13. Russia
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Diagnosis
15.13.2.2. By Treatment
15.13.2.3. By End User
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Diagnosis
15.14.2.2. By Treatment
15.14.2.3. By End User
15.15. Malaysia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Diagnosis
15.15.2.2. By Treatment
15.15.2.3. By End User
15.16. Singapore
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Diagnosis
15.16.2.2. By Treatment
15.16.2.3. By End User
15.17. Thailand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Diagnosis
15.17.2.2. By Treatment
15.17.2.3. By End User
15.18. Australia
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Diagnosis
15.18.2.2. By Treatment
15.18.2.3. By End User
15.19. New Zealand
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Diagnosis
15.19.2.2. By Treatment
15.19.2.3. By End User
15.20. GCC Countries
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Diagnosis
15.20.2.2. By Treatment
15.20.2.3. By End User
15.21. South Africa
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Diagnosis
15.21.2.2. By Treatment
15.21.2.3. By End User
15.22. Israel
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Diagnosis
15.22.2.2. By Treatment
15.22.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Diagnosis
16.3.3. By Treatment
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. B. Braun SE
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Becton, Dickinson, and Company
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Bicakcilar
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Biometrix
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Cook Medical
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Grena
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Redax
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Rocket Medical
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Smith Medical
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Taiho Pharmaceutical Co., Ltd
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Malignant Pleural Effusion Market
